Short Interest in Genprex (NASDAQ:GNPX) Grows By 121.9%

Genprex (NASDAQ:GNPX) was the target of a significant growth in short interest during the month of April. As of April 30th, there was short interest totaling 1,121,624 shares, a growth of 121.9% from the April 15th total of 505,519 shares. Based on an average daily volume of 1,951,059 shares, the short-interest ratio is presently 0.6 days. Currently, 10.8% of the company’s stock are sold short.

Genprex Stock Down 3.6%

Shares of NASDAQ GNPX opened at $0.83 on Friday. The firm’s 50-day moving average price is $1.42 and its two-hundred day moving average price is $2.40. Genprex has a 52-week low of $0.81 and a 52-week high of $55.00. The stock has a market capitalization of $8.79 million, a P/E ratio of -0.03 and a beta of -0.94.

Genprex (NASDAQ:GNPX) last issued its earnings results on Wednesday, May 13th. The company reported ($0.64) EPS for the quarter.

Hedge Funds Weigh In On Genprex

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Susquehanna International Group LLP lifted its stake in Genprex by 11.7% in the third quarter. Susquehanna International Group LLP now owns 340,056 shares of the company’s stock valued at $58,000 after buying an additional 35,661 shares during the last quarter. Mayflower Financial Advisors LLC bought a new stake in Genprex in the first quarter valued at $36,000. Finally, Manchester Financial Inc. bought a new stake in Genprex in the first quarter valued at $36,000. 14.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on GNPX shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genprex in a research report on Tuesday, April 21st. Wall Street Zen upgraded Genprex from a “sell” rating to a “hold” rating in a research note on Saturday. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Genprex has an average rating of “Sell”.

About Genprex

Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.